RESUMO
Como continuación de nuestro trabajo publicado con anterioridad de igual título como parte 1ª [Sanidad Militar 2007;64(2):118-127], presentamos el resto de fármacos que han sido comercializados en nuestro país durante el pasado año 2006, con atención a sus diversas características, algunas de ellas reflejadas en su ficha técnica, y otras comentadas para complementar su conocimiento (AU)
As a continuation of our previous article published with the same title as first part [Sanidad Militar 2007;64(2):118-127], we present the other drugs that have been commercialized in our country during 2006. They are presented in accordance with their different characteristics, some of them described in the technical data sheet and other commented in order to complement their knowledge. The active principles that we present in this second part represent, as has already been stated previously, a reduced contribution from the innovation point of view. However for certain patients or group of patients, and in concrete circumstances, they may represent a specific solution for a case that might have a worse outlook without this contribution. The drugs that we present in order to complete those commercialized during 2006 are the following (AU)
Assuntos
Humanos , Drogas em Investigação/análise , Aplicação de Novas Drogas em Teste , Medicamentos de Referência , Sintase do Porfobilinogênio , Razoxano , Hormônio ParatireóideoRESUMO
Cada año la Agencia Española de Medicamentos evalúa la documentación correspondiente a los fármacos que le son presentados con propuesta para su registro y aprobación. Otros fármacos lo hacen a través de la Agencia Europea. En nuestro país se han autorizado veinticuatro principios activos durante el pasado año 2006. Se presentan y comentan los datos correspondientes a aquellos considerados por los autores de mayor interés. Tres principios son considerados como «Innovación excepcional», y uno más es considerado «Innovación importante ». El resto presentan mejoras menores aunque en determinadas circunstancias o en pacientes específicos pueden llegar a ser la alternativa de mayor interés (AU)
No disponible
Assuntos
Humanos , Drogas em Investigação/normas , /métodos , Medicamentos de Referência , Aplicação de Novas Drogas em Teste/organização & administração , Oxibato de Sódio , DaptomicinaRESUMO
OBJECTIVES: The present article summarizes the latest advancements in the physiology of erection, with special reference to the role of the adenylate and guanylate cyclase-nitric oxide system. METHODS/RESULTS: New aspects in the pharmacological intracavernous treatment of erectile dysfunction are discussed and new drugs in this field are analyzed, such as nitrovasodilators, calcium channel blocker, potassium channel openers, phosphodiesterase inhibitors and the combination of adenylate cyclase stimulators. CONCLUSIONS: A high percentage of patients with erectile dysfunction depends on intracavernous injection of vasoactive drugs for erection. However, this route of administration is painful and causes anxiety in many cases. Other routes of administration (oral, topical or intraurethral) have yet to be developed, as well as drugs that can diminish penile venous blood outflow in cases with venous leakage, and can enhance arterial blood supply at the same time. The combination of phosphodiesterase inhibitors with adenylate and/or guanylate cyclase stimulators or potassium channel openers may further enhance the results achieved to date.
